MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
